ArticleCell death & disease2026
AURKA suppresses NCOA4-mediated ferritinophagy to enhance sorafenib resistance in hepatocellular carcinoma.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remodeling of ferroptotic necroinflammation by dexamethasone in acute tubular necrosis.Cell death & disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Acquired resistance to sorafenib remains a major obstacle in the treatment of advanced hepatocellular carcinoma (HCC). While inducing ferroptosis represents a promising strategy to overcome this resistance, the specific molecular drivers underlying ferroptosis evasion in this context remain poorly defined. Here, we identified Aurora Kinase A (AURKA) as a central, actionable regulator of ferroptosis resistance in sorafenib-resistant HCC. AURKA was significantly upregulated in resistant cells and clinical specimens, which correlated with a suppressed ferroptotic state. Mechanistically, we discovered that AURKA directly interacted with and phosphorylated the ferritinophagy receptor NCOA4 at specific serine residues (S186/S234/S492), thereby competitively disrupting the NCOA4-FTH1 complex. This disruption inhibited ferritinophagic degradation of FTH1, stabilized the iron-storage protein, and limited the intracellular labile iron pool required for ferroptosis execution. Genetic or pharmacological inhibition of AURKA restored NCOA4-mediated ferritinophagy, synergized with ferroptosis inducers (sorafenib or IKE), and potently suppressed tumor growth both in vitro and in vivo. Clinically, high co-expression of AURKA and FTH1 predicted an unfavorable prognosis of HCC patients. Our study delineated the first direct link between AURKA kinase activity and the ferritinophagy machinery, establishing the AURKA-NCOA4-FTH1 axis as a master regulator of ferroptosis resistance in sorafenib-resistant HCC. These findings provide both a novel prognostic biomarker and a mechanistically grounded therapeutic strategy to overcome acquired resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.